Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies

@inproceedings{Besser2013DevelopmentOA,
  title={Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies},
  author={Michal J Besser and Tsipi Shoham and Orit Harari-Steinberg and Naama Zabari and Rona Ortenberg and Arkadi Yakirevitch and Arnon Nagler and Ron Loewenthal and Jacob M Schachter and Gal Markel},
  booktitle={PloS one},
  year={2013}
}
Natural killer (NK) cells have long been considered as potential agents for adoptive cell therapy for solid cancer patients. Until today most studies utilized autologous NK cells and yielded disappointing results. Here we analyze various modular strategies to employ allogeneic NK cells for adoptive cell transfer, including donor-recipient HLA-C mismatching, selective activation and induction of melanoma-recognizing lysis receptors, and co-administration of antibodies to elicit antibody… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Cell Transfer Therapy for Cancer: Past, Present, and Future

  • Journal of immunology research
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 52 REFERENCES

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Recognition of viral hemagglutinins by NKp44 but not by NKp30.

  • European journal of immunology
  • 2001
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Systemic dysregulation of CEACAM1 in melanoma patients

  • Cancer Immunology, Immunotherapy
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…